LEADER 00000nam a22005173i 4500 
001    EBC1574351 
003    MiAaPQ 
005    20200713055255.0 
006    m     o  d |       
007    cr cnu|||||||| 
008    200713s2014    xx      o     ||||0 eng d 
020    9781118590614|q(electronic bk.) 
020    |z9780470621882 
035    (MiAaPQ)EBC1574351 
035    (Au-PeEL)EBL1574351 
035    (CaPaEBR)ebr10814726 
035    (CaONFJC)MIL548134 
035    (OCoLC)864746032 
040    MiAaPQ|beng|erda|epn|cMiAaPQ|dMiAaPQ 
050  4 RC280.S5.D476 2014eb 
082 0  616.99/477 
100 1  Lacouture, Mario E 
245 10 Dermatologic Principles and Practice in Oncology :
       |bConditions of the Skin, Hair, and Nails in Cancer 
       Patients 
250    1st ed 
264  1 Somerset :|bJohn Wiley & Sons, Incorporated,|c2014 
264  4 |c©2013 
300    1 online resource (442 pages) 
336    text|btxt|2rdacontent 
337    computer|bc|2rdamedia 
338    online resource|bcr|2rdacarrier 
505 0  Cover -- Title page -- Copyright page -- Contents -- List 
       of Contributors -- Preface -- 1: Dermatology and Oncology 
       -- 1: Epidemiology and Burden of Disease -- Introduction -
       - Dermatologic health in cancer patients and survivors -- 
       Financial burden -- Health-related quality of life -- 
       Dosing of chemotherapy -- Conclusions -- References -- 
       Appendix 1.1 Anticancer agents and associated adverse 
       events affecting the skin, mucosa, hair, and nails. Based 
       on data from Litt JZ, 2009 [8]. -- 2: The History of 
       Supportive Oncodermatology -- Evolution of anticancer 
       therapeutics -- Spectrum of dermatologic adverse events 
       stemming from conventional cytotoxic chemotherapy agents -
       - Radiation and surgery-induced mucocutaneous toxicities -
       - Mucocutaneous toxicities induced by novel targeted 
       agents -- Emergence of supportive oncodermatology and 
       future directions -- References -- 3: Structure and 
       Function of the Integumentary System and the Dermatology 
       Lexicon -- Introduction -- Skin -- Epidermis -- Dermal-
       epidermal junction -- Dermis -- Vasculature -- Nerves -- 
       Subcutaneous tissue -- Appendages -- Eccrine sweat glands 
       -- Apocrine sweat glands -- Sebaceous glands -- Hair -- 
       Nails -- Morphology -- Raised lesions -- Papule -- Plaque 
       -- Nodule -- Cyst -- Wheal -- Depressed lesions -- Erosion
       -- Ulcer -- Atrophy -- Poikiloderma -- Flat lesions -- 
       Macule -- Patch -- Sclerosis -- Erythema -- Erythroderma -
       - Fluid-filled lesions -- Vesicle and bulla -- Pustule -- 
       Furuncle -- Abscess -- Surface changes -- Scale -- Crust -
       - Eschar -- Purpura and vascular lesions -- Purpura -- 
       Infarct -- Shape, configuration, arrangement, and 
       distribution of lesions -- Conclusions -- 4: Types of 
       Dermatologic Reactions -- Exanthematous eruptions -- 
       Urticarial eruptions -- Lichenoid eruptions -- Acneiform 
       eruptions -- Pustular eruptions (acute generalized 
       exanthematous pustulosis) 
505 8  Bullous eruptions -- Drug-induced vasculitis -- 
       Erythroderma -- Approach to patients with suspected drug 
       eruption -- Step 1: Recognizing the morphology -- Step 2: 
       Associated symptoms and systemic involvement -- Step 3: 
       Histopathologic assessment -- Step 4: Determining the 
       offending drug -- Conclusions -- References -- 5: Grading 
       Dermatologic Adverse Events in Clinical Trials Using CTCAE
       v4.0 -- Common Terminology Criteria for  Adverse Events --
       CTCAE grade scale -- Attribution -- Changes in CTCAE V4.0 
       -- Refined grading to correlate with clinical management -
       - Alopecia -- Rash acneiform -- Skin hyperpigmentation -- 
       Split of embedded terms -- Rash maculopapular -- 
       Erythroderma -- Bullous dermatitis -- Nail discoloration, 
       nail ridging, and nail loss -- New adverse events -- 
       Hypertrichosis -- Hypohidrosis -- Lipohypertrophy -- 
       Periorbital edema -- Moved to different SOC -- 
       Papulopustular rash -- Rash pustular -- Paronychia -- 
       CTCAE vs. MESTT -- Conclusions -- References -- 6: 
       Psychosocial Issues in Oncology: Clinical Management of 
       Psychosocial Distress, Health-Related Quality of Life, and
       Special Considerations in Dermatologic Oncology -- 
       Psychosocial distress -- Distress among dermatologic 
       samples -- Dermatologic AEs from cancer treatment -- Risk 
       factors for distress -- Clinical management of distress --
       Measuring distress and health-related quality of life in 
       dermatologic oncology -- Psychosocial interventions in 
       oncodermatology -- Conclusions -- References -- 7: 
       Dermatopathology -- Introduction -- Mucocutaneous 
       neoplasms -- Solar (actinic) keratosis -- Squamous cell 
       carcinoma -- Melanocytic tumors -- Inflammatory dermatoses
       -- Interface (lichenoid) dermatitis -- Spongiotic 
       dermatitis -- Superficial or superficial and deep 
       perivascular lymphohistiocytic inflammation -- Suppurative
       and granulomatous dermatitis -- Conclusions -- References 
505 8  2: Cancer-Related Dermatologic Disorders -- 8: 
       Paraneoplastic, Inherited Cancer Syndrome, and 
       Environmental Carcinogen-Related Dermatoses -- 
       Paraneoplastic disorders -- Skin changes from hormone-
       secreting tumors -- Ectopic ACTH-producing tumors -- 
       Proliferative and inflammatory paraneoplastic dermatoses -
       - Inherited syndromes with increased cancer risk and skin 
       effects -- Muir-Torre syndrome -- Gardner syndrome -- 
       Cowden syndrome -- Peutz-Jeghers syndrome -- Birt-Hogg-
       Dubé -- Howel-Evans syndrome -- Hereditary leiomyomatosis/
       renal cell cancer syndrome -- Environmental carcinogens 
       with increased cancer risk and skin effects -- Arsenic -- 
       Vinyl chloride -- Ionizing radiation -- References -- 3: 
       Dermatologic Conditions During Cancer Therapy -- 9: Oral 
       Mucosal Complications of Cancer Therapy -- Introduction --
       Mucosal injury attributable to cytotoxic therapy -- 
       Clinical features and course of mucositis -- Mucositis 
       scoring -- Clinician-based scoring -- Toxicity description
       and assessment -- Patient management scales -- Research-
       directed scales -- Variability between mucositis scales --
       Patient-reported instruments to assess mucositis severity 
       -- Minimizing inter-observer variability in mucositis 
       assessment -- Impact of mucositis -- Pathobiology of 
       mucositis -- Signal amplification -- Risk factors for 
       mucositis -- The oral environment and mucositis -- Status 
       of the development of therapies for mucositis -- Mucosal 
       changes associated with targeted therapies -- Mucosal 
       injury associated with mTOR inhibitors -- Small molecules 
       and antibodies -- Oral manifestations of graft versus host
       disease -- Conclusions -- References -- 10: Hair Disorders
       Associated with Anticancer Agents -- Introduction -- Basic
       hair anatomy and function -- Types of chemotherapy-induced
       hair loss/alopecia -- Telogen effluvium -- Anagen 
       effluvium -- Abnormal hair growth 
505 8  Permanent chemotherapy-induced alopecia -- Radiation-
       induced alopecia -- Grading scales utilized for 
       determining degree of hair loss or regrowth -- Potential 
       treatments for chemotherapy-induced alopecia -- Prevention
       of hair loss -- Acceleration of regrowth after 
       chemotherapy -- Conclusions -- References -- 11: Nail 
       Abnormalities in Oncology Practice -- Introduction -- 
       Drugs -- Classic cytotoxic drugs -- Epidermal growth 
       factor receptor inhibitors -- Symptoms -- Nail matrix and 
       nail plate alterations -- Nail fold involvement -- Nail 
       bed involvement -- Digit tip xerosis -- Classification -- 
       Treatment -- Prevention -- Conclusions -- References -- 12
       : Pruritus -- Introduction -- Cutaneous diseases -- 
       Systemic and psychiatric diseases -- Malignancy -- Therapy
       -- Clinical findings -- Visual analog scale for pruritus -
       - Management -- General principles -- Topical treatments -
       - Systemic treatments -- Physical treatments -- 
       Phototherapy -- Bio-behavioral therapy -- Conclusions -- 
       References -- 13: Management Options for Hot Flashes in 
       Cancer Patients -- Introduction -- Grading of hot flashes 
       -- Treatment of hot flashes -- Pharmacologic interventions
       -- Nonpharmacologic interventions -- Behavioral therapies 
       -- Physical measures -- Conclusions and recommendations --
       References -- 4: Skin Toxicities to Chemotherapy -- 14: 
       Alkylating Agents -- Introduction -- Nitrogen mustards -- 
       Mustargen (mechlorethamine) -- Cyclophosphamide -- 
       Ifosfamide -- Melphalan -- Chlorambucil -- Aziridines and 
       epoxides -- ThioTEPA -- Mitomycin C -- Alkyl sulfonates --
       Busulfan -- Nitrosoureas -- Carmustine 
       (bischloroethylnitrosourea) -- Streptozocin -- Hydrazines 
       and triazine derivatives -- Procarbazine -- Dacarbazine --
       Temozolomide -- Hydroxurea -- References -- 15: 
       Antimetabolite Reactions -- Introduction -- Methotrexate -
       - Pemetrexed -- Capecitabine -- Cytarabine -- Gemcitabine 
505 8  Mercaptopurine -- Thioguanine -- Fludarabine -- Cladribine
       -- References -- 16: Topoisomerase-Interacting Agents -- 
       Introduction -- Topoisomerase I inhibitors -- Irinotecan 
       and topotecan -- Topoisomerase II inhibitors -- 
       Anthracyclines: Doxorubicin, liposomal doxorubicin, 
       epirubicin and idarubicin -- Etoposide and teniposide -- 
       Mitoxantrone -- Alopecia -- Hand-foot syndrome -- 
       Hyperpigmentation -- Intertrigo -- Nail changes -- 
       Extravasation of topoisomerase inhibitors -- Stevens-
       Johnson syndrome -- Mucositis -- Radiation recall -- 
       References -- 17: Epidermal Growth Factor Receptor 
       Inhibitor Reactions -- Introduction -- Epidermal growth 
       factor receptor inhibitors -- Dermatologic adverse events 
       of EGFRIs -- Papulopustular (acneiform) rash -- Xerosis 
       and pruritus -- Hyperpigmentation -- Telangiectasias -- 
       Mucosal toxicities -- Hair alterations -- Nail and 
       periungual involvement -- Interaction of EGFRIs with 
       conventional cytotoxic chemotherapy and radiotherapy -- 
       Conclusions -- References -- 18: Small Molecule 
       Multikinase Inhibitors -- Introduction -- Kit, PDGFR and 
       bcr-abl inhibitors: imatinib, nilotinib, dasatinib -- 
       Drugs, indications, and mechanisms of action -- 
       Antiangiogenic agents: sorafenib, sunitinib axitinib, 
       regorafenib, and pazopanib -- Hand-foot skin reaction -- 
       Subungual splinter hemorrhages -- Erythematous rashes -- 
       Hair modifications -- Xerosis -- Genital involvement -- 
       Mucositis -- AEs specifically related to sunitinib -- AEs 
       related specifically to sorafenib -- mTOR inhibitors: 
       everolimus and temsirolimus -- Drugs and mechanisms of 
       action -- Skin manifestations -- Conclusions -- References
       -- 19: Antimicrotubule Agents -- Introduction -- Taxanes -
       - Clinical features -- Treatment of choice and prognosis -
       - Vinca alkaloids -- Clinical features -- Treatment of 
       choice and prognosis -- Estramustine phosphate sodium -- 
       References 
505 8  20: Histone Deacetylase Inhibitors, Proteasome Inhibitors,
       Demethylating Agents, Arsenicals, and Retinoids 
520    List of Contributors, vii   Preface, x   Section 1 
       Dermatology and Oncology   1 Epidemiology and Burden of 
       Disease, 3Beth N. McLellan, Devika Patel and Mario E. 
       Lacouture   2 The History of Supportive Oncodermatology, 
       17Yevgeniy Balagula, Steven T. Rosen and Mario E. 
       Lacouture   3 Structure and Function of the Integumentary 
       System and the Dermatology Lexicon, 24Emmy Graber and Amit
       Garg   4 Types of Dermatologic Reactions, 33Raed O. 
       Alhusayen, Sandra R. Knowles and Neil H. Shear   5 Grading
       Dermatologic Adverse Events in Clinical Trials Using CTCAE
       v4.0, 47Alice Chen, Asha Acharya and Ann Setser   6 
       Psychosocial Issues in Oncology: Clinical Management of 
       Psychosocial Distress, Health-Related Quality of Life, and
       Special Considerations in Dermatologic Oncology, 60Lynne 
       I. Wagner and David Cella   7 Dermatopathology, 69Molly A.
       Hinshaw and James L. Troy   Section 2 Cancer-Related 
       Dermatologic Disorders   8 Paraneoplastic, Inherited 
       Cancer Syndrome, and Environmental Carcinogen-Related 
       Dermatoses, 77Cindy England Owen and Jeffrey P. Callen   
       Section 3 Dermatologic Conditions During Cancer Therapy   
       9 Oral Mucosal Complications of Cancer Therapy, 89Stephen 
       T. Sonis   10 Hair Disorders Associated with Anticancer 
       Agents, 100Caroline Yeager and Elise A. Olsen   11 Nail 
       Abnormalities in Oncology Practice, 115Robert Baran, 
       Bernard Fouilloux and Caroline Robert   12 Pruritus, 
       122Tejesh Patel and Gil Yosipovitch   13 Management 
       Options for Hot Flashes in Cancer Patients, 131Amanda R. 
       Moraska and Charles L. Loprinzi   Section 4 Skin 
       Toxicities to Chemotherapy   14 Alkylating Agents, 
       147Elisabeth Livingstone, Lisa Zimmer, Larissa Leister and
       Dirk Schadendorf   15 Antimetabolite Reactions, 160Emily 
       Y. Chu and Heidi H. Kong   16 Topoisomerase-Interacting 
       Agents, 170Tomas Skacel, Roger von Moos and Reinhard 
       Dummer   17 Epidermal Growth Factor Receptor Inhibitor 
520 8  Reactions, 184Yevgeniy Balagula and Mario E. Lacouture   
       18 Small Molecule Multikinase Inhibitors, 196Caroline 
       Robert, Vincent Sibaud and Christine Mateus   19 
       Antimicrotubule Agents, 208Claus Garbe   20 Histone 
       Deacetylase Inhibitors, Proteasome Inhibitors, 
       Demethylating Agents, Arsenicals, and Retinoids, 215Najla 
       Al-Dawsari, Shannon C. Trotter and Francine Foss   21 
       Miscellaneous Reactions, 224Katharina C. Kaehler, 
       Christine B. Boers-Doets, Mario E. Lacouture and Axel 
       Hauschild   22 Skin Toxicities due to Biotherapy, 
       233Kathryn T. Ciccolini, Katharina C. Kaehler, Mario E. 
       Lacouture and Axel Hauschild   23 Monoclonal Antibodies, 
       241Caroline Robert   24 Endocrine Agents, 248Katherine 
       Szyfelbein Masterpol, Maura Dickler and Mario E. Lacouture
       25 Agents for the Management of Hematologic Reactions, 
       257Mee-young Lee and Caroline C. Kim   26 Radiation-
       Induced Skin Reactions, 264Rebecca K.S. Wong and Zahra 
       Kassam   27 Hematopoietic Stem Cell Transplantation and 
       Graft Versus Host Disease, 281Stephanie W. Hu and Jonathan
       Cotliar   28 Extravasation Reactions, 295Seppo W. Langer  
       29 Topical Anticancer Therapies, 301Patricia L. Myskowski 
       30 Life-threatening (Serious) Dermatologic Adverse Events,
       310Milan J. Anadkat   31 Dermatologic Infections, 
       319Yevgeniy Balagula, Mario E. Lacouture and James I. Ito 
       Section 5 Late Cutaneous Events from Cancer Treatment   32
       Late Dermatologic Conditions, 339Jennifer Nam Choi   
       Section 6 Dermatologic Practice in Oncology   33 
       Management Algorithms for Dermatologic Adverse Events, 
       367Alyx Rosen, Iris Amitay-Laish and Mario E. Lacouture   
       34 Dermatologic Therapeutics and Formulations, 384Judy H. 
       Borovicka, Jennifer R.S. Gordon, Ann Cameron Haley, Nicole
       E. Larsen and Dennis P. West   35 Dermatologic Techniques 
       and Procedures, 401Robert Eilers Jr., Kishwer S. Nehal and
       Erica H. Lee   36 Appearance-Related Concerns in the 
520 8  Cancer Patient, 410Amy J. Derick   Index, 417 
588    Description based on publisher supplied metadata and other
       sources 
590    Electronic reproduction. Ann Arbor, Michigan : ProQuest 
       Ebook Central, 2020. Available via World Wide Web. Access 
       may be limited to ProQuest Ebook Central affiliated 
       libraries 
650  0 Skin -- Diseases -- Etiology.;Skin -- Diseases -- 
       Psychology.;Tumors -- Complications 
655  4 Electronic books 
776 08 |iPrint version:|aLacouture, Mario E.|tDermatologic 
       Principles and Practice in Oncology : Conditions of the 
       Skin, Hair, and Nails in Cancer Patients|dSomerset : John 
       Wiley & Sons, Incorporated,c2014|z9780470621882 
856 40 |uhttps://ebookcentral.proquest.com/lib/sinciatw/
       detail.action?docID=1574351|zClick to View